Cullinan Therapeutics (CGEM) FCF Payout Ratio (2024)
Cullinan Therapeutics' (CGEM) quarterly FCF Payout Ratio came in at 0.02 in Q3 2024, up 81.61% quarter-over-quarter from 0.1 in Q2 2024.
Cullinan Therapeutics (CGEM) FCF Payout Ratio (2024) Analysis & Trends
Cullinan Therapeutics' FCF Payout Ratio history runs 1 years deep, the most recent figure standing at 0.02 for Q3 2024.
- On a quarterly basis, FCF Payout Ratio changed N/A year-over-year to 0.02 in Q3 2024; TTM through Dec 2025 was 0.0, a 87.81% increase from a year earlier, with the FY2024 full-year figure at 0.03, changed N/A from the prior year.
- FCF Payout Ratio improved to 0.02 in Q3 2024 per CGEM's latest filing, from 0.1 in the prior quarter.
- Across five years, FCF Payout Ratio topped out at 0.02 in Q3 2024 and bottomed at 0.1 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.12 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cullinan Therapeutics | 368.65 Mn | 368.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -0.02 |
| Jun 30, 2024 | -0.10 |